Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results
Posted innews Oncology

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results

Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combination as an additional frontline option, especially where other immunotherapy regimens are unavailable.
Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial
Posted inGastroenterology news Oncology

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial

The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation in 26% of patients with pMMR/MSS stage II–III rectal cancer.
A Standardized RANO Resection Classification Links Supramaximal Surgery to Meaningful Survival Gains in IDH‑Mutant Grade 2 Glioma
Posted inNeurology news Oncology

A Standardized RANO Resection Classification Links Supramaximal Surgery to Meaningful Survival Gains in IDH‑Mutant Grade 2 Glioma

An international retrospective cohort (n=1,391) validates a four‑tier RANO classification of residual T2‑FLAIR volume: supramaximal resection confers the largest survival benefit, with graded, durable advantages for maximal versus submaximal resections across IDH‑mutant astrocytoma and oligodendroglioma.
Microbubble‑Enhanced Focused Ultrasound with Temozolomide Shows Feasibility and Promising Survival in High‑Grade Glioma — Phase 1/2 Multicentre Results
Posted inNeurology news Oncology

Microbubble‑Enhanced Focused Ultrasound with Temozolomide Shows Feasibility and Promising Survival in High‑Grade Glioma — Phase 1/2 Multicentre Results

A multicentre phase 1/2 trial reports that MRI‑guided microbubble‑enhanced transcranial focused ultrasound (MB‑FUS) can safely open the blood–brain barrier and be combined with standard adjuvant temozolomide in high‑grade glioma, with median overall survival 31.3 months and feasibility for non‑invasive plasma biomarker monitoring.
High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action
Posted inHIV/AIDS Infectious Diseases news

High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action

A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and poor adherence, highlighting the need for monitoring and adherence support.
Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications
Posted inCardiology news Public Health

Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications

A life cycle assessment found SAVR emits ~620–750 kg CO2e per case—roughly double OR- or cath-lab TAVR (~280–360 kg CO2e). ICU length of stay and postoperative care were the dominant contributors, highlighting targets for low-carbon perioperative pathways and policy-level decision-making.
SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset
Posted innews Oncology Respiratory

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurring KRAS and STK11/KEAP1 alterations—are immune‑cold and have poor outcomes despite chemoimmunotherapy.
Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis
Posted inCardiology news

Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis

In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associated with lower mortality. Combined therapy produced outcomes comparable to lone AS treated with AVR.
DOACs trong Bệnh Nhân Rối Loạn Nhịp Tim Atrial Rất Cao Tuổi và Nguy Cơ Xuất Huyết Cao: Một Đội Ngũ Toàn Quốc Hàn Quốc Cho Thấy Lợi Ích Lâm Sàng Tổng Thể
Posted innews

DOACs trong Bệnh Nhân Rối Loạn Nhịp Tim Atrial Rất Cao Tuổi và Nguy Cơ Xuất Huyết Cao: Một Đội Ngũ Toàn Quốc Hàn Quốc Cho Thấy Lợi Ích Lâm Sàng Tổng Thể

Trong một đội ngũ toàn quốc Hàn Quốc gồm bệnh nhân rối loạn nhịp tim atrial (AF) từ 80 tuổi trở lên có nguy cơ xuất huyết cao, các chất chống đông máu đường uống trực tiếp (DOACs) đã giảm thiểu đột quỵ thiếu máu não và tử vong do mọi nguyên nhân so với không sử dụng thuốc chống đông máu, mặc dù có nguy cơ xuất huyết lớn hơn; tổng thể kết quả lâm sàng tổng thể ủng hộ việc sử dụng DOACs.
Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)
Posted inCardiology news

Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)

Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the need for individualized strategies in the very elderly.
High Early Risk of Sudden Cardiac Arrest in Newly Diagnosed Cardiomyopathy: Insights from the German SCD‑PROTECT Wearable Defibrillator Registry
Posted inCardiology news

High Early Risk of Sudden Cardiac Arrest in Newly Diagnosed Cardiomyopathy: Insights from the German SCD‑PROTECT Wearable Defibrillator Registry

The nationwide SCD‑PROTECT study (n=19,598) found substantial early risk of sustained VT/VF in newly diagnosed ischaemic and non‑ischaemic cardiomyopathy; wearable cardioverter‑defibrillators (WCDs) delivered life‑saving therapy with low inappropriate shock rates while ~52% recovered LVEF >35% during a mean 66‑day WCD period.